⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6593109 | 0.80 | — | — | |
| SCHEMBL14124538 | 0.79 | — | — | |
| SCHEMBL507903 | 0.74 | — | — | |
| SCHEMBL177681 | 0.74 | — | — | |
| SCHEMBL13067260 | 0.74 | — | — | |
| SCHEMBL469221 | 0.74 | — | — | |
| Hydrochloric Acid SCHEMBL70364 | 0.74 | — | — | |
| SCHEMBL1274803 | 0.74 | — | — | |
| SCHEMBL28764737 | 0.73 | — | — | |
| SCHEMBL14451325 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107344940-B | BTK inhibitors and uses thereof | 广东东阳光药业有限公司 | 2020-04-21 | — | — | CN | claimed |
| US-9139567-B2 | Arylpyrazole ethers as inhibitors of leukotriene A4 hydrolase | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-09-22 | — | — | US | claimed |
| US-20140221373-A1 | ARYLPYRAZOLE ETHERS AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-08-07 | — | — | US | claimed |
| EP-2734516-A1 | ARYLPYRAZOLE ETHERS AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | Boehringer Ingelheim International GmbH (DE) | 2014-05-28 | — | — | EP | claimed |
| WO-2013012844-A1 | ARYLPYRAZOLE ETHERS AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-24 | — | — | WO | claimed |
| JP-2011524881-A | — | — | 2011-09-08 | — | — | JP | claimed |
| CN-102123991-A | 2-arylaminoquinazolines for the treatment of proliferative diseases | NOVARTIS AG | 2011-07-13 | — | — | CN | claimed |
| EP-2307385-A1 | 2 -ARYLAMINOQUINAZOLINES FOR TREATING PROLIFERATIVE DISEASES | Novartis AG (CH) | 2011-04-13 | — | — | EP | claimed |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | JAIN RAMA | 2010-05-13 | — | — | US | claimed |
| WO-2009153313-A1 | 2 -ARYLAMINOQUINAZOLINES FOR TREATING PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2009-12-23 | — | — | WO | claimed |
| US-20080214648-A1 | Hiv Prodrugs Cleavable by Cd26 | DE KOCK HERMAN AUGUSTINUS | 2008-09-04 | — | — | US | claimed |
| EP-1624897-B1 | HIV PRODRUGS CLEAVABLE BY CD26 | TIBOTEC PHARM LTD (IE) | 2007-10-10 | — | — | EP | claimed |
| CN-1906155-A | Novel hydroxamic acid esters and pharmaceutical use thereof | LEO PHARMA AS (DK) | 2007-01-31 | — | — | CN | claimed |
| US-20070015743-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | US | claimed |
| CN-1882572-A | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2006-12-20 | — | — | CN | claimed |
| CN-1784244-A | HIV prodrugs cleavable by CD26 | TIBOTEC PHARM LTD (IE) | 2006-06-07 | — | — | CN | claimed |
| WO-2023227118-A1 | 3C-LIKE PROTEASE INHIBITOR | 广州国家实验室 | 2023-11-30 | — | — | WO | disclosed |
| EP-4219477-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-08-02 | — | — | EP | disclosed |
| US-4918070-A | Antibiotics | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1990-04-17 | — | — | US | disclosed |
| EP-0280240-A2 | Cephalosporin derivatives, process for their preparation and antibacterial agents | Banyu Pharmaceutical Co., Ltd. (JP) | 1988-08-31 | — | — | EP | disclosed |